From Nasdaq: 2025-05-28 04:15:00

The weight loss drug market is booming, with Novo Nordisk leading with semaglutide in Ozempic and Wegovy. However, competition is rising with next-gen drugs in development. Market could reach $150 billion by 2035, with Novo Nordisk holding 62% market share. Competition includes Eli Lilly’s orforglipron. Novo Nordisk aims for regulatory approval for pill-form Wegovy and has CagriSema in clinical trials. Despite fears of competition, Novo Nordisk’s stock slide may present a buying opportunity, trading at a P/E ratio of 20. Pharmaceutical business risks exist, but Novo Nordisk remains a strong industry leader.



Read more at Nasdaq: Novo Nordisk’s 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?